The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Reading RHEUM

Reading RHEUM

November 1, 2006 • By Robyn T. Domsic, MD; Kathleen A. Haines, MD; Daniel H. Solomon, MD, MPH;

  • Tweet
  • Email
Print-Friendly Version / Save PDF

CARDIOVASCULAR

RUTH Trial Urges Caution when Prescribing Raloxifene

By Robyn T. Domsic, MD

You Might Also Like
  • Reading Rheum
  • Reading Rheum: Which Bone Agent Is Best in High-risk Osteoporosis?
  • Reading Rheum
Explore This Issue
November 2006

Barrett-Connor E, Mosca L, Collins P, et al. for the Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women. NEJM. 2006;355:125-137.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Abstract

Background: The effect of raloxifene, a selective estrogen-receptor modulator, on coronary heart disease (CHD) and breast cancer is not established.

Methods: We randomly assigned 10,101 postmenopausal women (mean age, 67.5) with CHD or multiple risk factors for CHD to 60 mg of raloxifene daily or placebo and followed them for a median of 5.6 years. The two primary outcomes were coronary events (i.e., death from coronary causes, myocardial infarction, or hospitalization for an acute coronary syndrome) and invasive breast cancer.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Results: As compared with placebo, raloxifene had no significant effect on the risk of primary coronary events (533 versus 553 events; hazard ratio, 0.95; 95% confidence interval, 0.84 to 1.07), and it reduced the risk of invasive breast cancer (40 versus 70 events; hazard ratio, 0.56; 95% confidence interval, 0.38 to 0.83; absolute risk reduction, 1.2 invasive breast cancers per 1000 women treated for one year); the benefit was primarily due to a reduced risk of estrogen receptor–positive invasive breast cancers. There was no significant difference in the rates of death from any cause or total stroke according to group assignment, but raloxifene was associated with an increased risk of fatal stroke (59 versus 39 events; hazard ratio, 1.49; 95% confidence interval, 1.00 to 2.24; absolute risk increase, 0.7 per 1,000 woman-years) and venous thromboembolism (103 versus 71 events; hazard ratio, 1.44; 95% confidence interval, 1.06 to 1.95; absolute risk increase, 1.2 per 1,000 woman-years). Raloxifene reduced the risk of clinical vertebral fractures (64 versus 97 events; hazard ratio, 0.65; 95 % confidence interval, 0.47 to 0.89; absolute risk reduction, 1.3 per 1000).

TABLE 1: RUTH Trial Data
click for large version
TABLE 1: RUTH Trial Data

Conclusions: Raloxifene did not significantly affect the risk of CHD. The benefits of raloxifene in reducing the risks of invasive breast cancer and vertebral fracture should be weighed against the increased risks of venous thromboembolism and fatal stroke.

Commentary

The role of raloxifene in the prevention and treatment of osteoporosis has been in a state of flux because concerns about hormonal therapy arose with the Women’s Health Initiative trial. In patients unable to take a bisphosphonate, or in those who were merely osteopenic, raloxifene has nevertheless remained a treatment option. As we can recall, the MORE (Multiple Outcomes of Raloxifene Evaluation) trial, published in 1999, suggested a 30% relative risk reduction in vertebral fractures among women with osteoporosis treated for three years, and reported an increase in femoral neck and spine density with raloxifene.1 This drug was then approved for use in the treatment of postmenopausal osteoporosis by the Food and Drug Administration.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, Research Reviews, Rheumatoid Arthritis, Systemic Inflammatory Syndromes Tagged With: anti-tumor necrosis factor, bisphosphonates, Clinical research, dermatomyositis, Disease-modifying antirheumatic drugs (DMARDs), Heart Disease, Juvenile arthritis, juvenile dermatomyositis, Literature, RA, Raloxifen, Reading Rheum, Rheumatoid Arthritis (RA), tumor necrosis factor, vertebral fractureIssue: November 2006

You Might Also Like:
  • Reading Rheum
  • Reading Rheum: Which Bone Agent Is Best in High-risk Osteoporosis?
  • Reading Rheum
  • Reading Rheum

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)